Cargando…

Risk Awareness and Demographic Characteristics Associated With the Use of Sexual Enhancement Supplements Among University Staff: A Cross-Sectional Study in the United Arab Emirates

Sexual enhancement supplements (SESs) that have illegal additions of pharmaceuticals or analogues pose a significant health risk, particularly with long-term usage. When supplements are adulterated with phosphodiesterase type 5 (PDE-5) inhibitors, dosages can vary widely and there may be an increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Jairoun, Ammar Abdulrahman, Saleh Al-Hemyari, Sabaa, Shahwan, Moyad, Saeed, Balsam Qubais, Godman, Brian, Kurdi, Amanj, Zyoud, Samer H., Ibrahim, Baharudin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061647/
https://www.ncbi.nlm.nih.gov/pubmed/36987378
http://dx.doi.org/10.1177/15579883231158531
Descripción
Sumario:Sexual enhancement supplements (SESs) that have illegal additions of pharmaceuticals or analogues pose a significant health risk, particularly with long-term usage. When supplements are adulterated with phosphodiesterase type 5 (PDE-5) inhibitors, dosages can vary widely and there may be an increase in adverse effects and drug–drug interactions which cannot be avoided. Consequently, there is a need to evaluate the public risk awareness toward SES and the associated adverse events as well as explore significant factors associated with knowledge and risk awareness. A cross-sectional community-based study was conducted among University male students and staff at Ajman University, United Arab Emirates (UAE), using a self-administered survey via a web-based electronic link to explore key issues. A total of 1,101 male subjects participated in the study and completed the questionnaire. Four hundred and thirty-three(39.3%) (95% confidence interval [CI]: 33.2–44.5) participants reported using SES products. Of these, 137 (31.6%) [95% CI: 28.6–37.2] experienced adverse effects from SES product use. SES use was more prevalent among participants aged 60 to 69 years (odds ratio [OR]: 2.94; 95% CI: 1.63–5.28), diabetic patients (OR: 2.61; 95% CI: 1.75–3.90), hypertension patients (OR: 2.12; 95% CI: 1.45–3.1), and those overweight or obese (OR: 1.84; 95% CI: 1.44–2.35). This study indicates that SES is a popular practice among the UAE university staff and students. However, there is a need to implement risk awareness programs to raise public awareness regarding SES use and safety. Regulatory bodies are encouraged to provide additional advice on the proper use and possible risks of consuming SES.